Open AccessLYN kinase and estrogen receptor ERα: involvement in carcinogenesis and potential therapeutic target for tumors
Author(s) -
В. В. Тихонова,
Yu. P. Finashutina,
Л. А. Кесаева
Publication year - 2021
Publication title -
uspehi molekulârnoj onkologii
Language(s) - English
Resource type - Journals
eISSN - 2413-3787
pISSN - 2313-805X
DOI - 10.17650/2313-805x-2021-8-3-44-59
Subject(s) - lyn , estrogen receptor , cancer research , carcinogenesis , biology , signal transduction , proto oncogene tyrosine protein kinase src , kinase , targeted therapy , estrogen receptor alpha , cancer , bioinformatics , computational biology , microbiology and biotechnology , genetics , breast cancer
Primary or secondary resistance is an important problem when treating any type of tumor. It is often associated with changes in target genes’ functioning. This raises the question of understanding functional intracellular interactions of genes and proteins in oncological processes and therapeutic resistance occurring. When searching target proteins of targeted therapy, it is necessary to identify biomolecules, participating in cell signaling life, which differ significantly in normal and oncological processes and interact with a large number of pathways. It is also important that these biomolecules are not an artifact of tumor therapy or cell line cultivation, and that it is possible to influence them directly, obtaining complex effect. In addition, it is important to study changes occurring during therapy with the biomolecules, which include proto-oncogene of SRC family kinase LYN and gene of the estrogen receptor α ESR1. All these factors may help to overcome the emerging resistance.Objective – to study the way genes of SRC kinase LYN and estrogen receptor α ESR1 influence oncological processes and occurrence of therapeutic resistance.